Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Calibration Patents Under Scrutiny As Supreme Court Weighs How To Build On Law Of Nature

This article was originally published in The Pink Sheet Daily

Executive Summary

During oral arguments in Mayo v. Prometheus, justices question what standard to apply in assessing whether the correlation of a drug’s metabolites to proper dosage is patentable; ACLU petitions court to review Myriad gene patent case.

You may also be interested in...



Supreme Court Overturns Drug Calibration Patents, Creating Confusion In Biotech Realm

The court’s finding that Prometheus’ drug calibration test is unpatentable has left the biotech community reeling with uncertainty as to whether method of treatment claims, particularly those involving biomarkers, will be patent eligible.

Supreme Court Abstains From Drugs: Will Not Review J&J Vs. Abbott; Takes No Action On Gene Patents

The high court denied J&J’s request for review of a Federal Circuit decision that overturned a $1.67 billion jury verdict against Abbott’s Humira; it made no decision on ACLU’s petition for review of Myriad Genetics’ BRCA gene patents.

Personalized Medicine At Stake In Prometheus Patent Case, BIO Tells Supreme Court

The biotech and pharmaceutical industries oppose a broad ruling that would prevent patenting of medical processes and diagnostics. Mayo is challenging patents on the correlation between drug metabolites and proper dosage.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073136

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel